middle.news
TrivarX bets on Stabl-Im as funding pressure sharpens
4:55pm on Tuesday 29th of September, 2026 AEST
•
Healthcare
Read Story
TrivarX bets on Stabl-Im as funding pressure sharpens
4:55pm on Tuesday 29th of September, 2026 AEST
Key Points
$8.76 million FY2026 net loss, up from $943,231
$2.44 million cash at year-end after $1.51 million operating outflow
Stabl-Im MRI platform acquired and prioritised for clinical development
Planned Phase 1 study targets the second half of CY2026, subject to approvals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Trivarx (ASX:TRI)
OPEN ARTICLE